{
  "findings": [
    {
      "id": "Q01",
      "metric": "Fraction of tumor proteins represented in immunopeptidome",
      "value": "62.3% in vaccine/combination arm",
      "comparator_or_baseline": "37.3% without vaccination",
      "interpretation": "Broader antigen display was achieved after intratumoral mRNA vaccination.",
      "evidence_line_refs": [
        "L28"
      ]
    },
    {
      "id": "Q02",
      "metric": "Fraction of proteins represented in MHC-I peptidome",
      "value": "40.6% in vaccinated tumors",
      "comparator_or_baseline": "20.6% baseline",
      "interpretation": "The MHC-I-presented landscape expanded strongly after mRNA vaccination.",
      "evidence_line_refs": [
        "L29"
      ]
    },
    {
      "id": "Q03",
      "metric": "Retrospective human survival comparison p-value",
      "value": "p=0.01 for vaccinated subgroup",
      "comparator_or_baseline": "Unvaccinated subgroup under ICI",
      "interpretation": "Vaccinated patients had improved survival while receiving ICI treatment.",
      "evidence_line_refs": [
        "L30"
      ]
    },
    {
      "id": "Q04",
      "metric": "Type I interferon response score (normalized units)",
      "value": "3.1 after vaccination",
      "comparator_or_baseline": "1.0 prior",
      "interpretation": "Type I interferon signaling was markedly induced by the mRNA vaccine.",
      "evidence_line_refs": [
        "L31"
      ]
    },
    {
      "id": "Q05",
      "metric": "PD-L1 expression fold-change in tumor tissue",
      "value": "2.4x with combination therapy",
      "comparator_or_baseline": "1.0x baseline",
      "interpretation": "The checkpoint axis became more targetable after the vaccine plus anti-PD-L1 intervention.",
      "evidence_line_refs": [
        "L32"
      ]
    },
    {
      "id": "Q06",
      "metric": "Intratumoral CD8+ T-cell density fold-change",
      "value": "1.8x with combination therapy",
      "comparator_or_baseline": "1.0x baseline",
      "interpretation": "Combination therapy increased immune infiltration in tumors.",
      "evidence_line_refs": [
        "L33"
      ]
    }
  ],
  "controls_or_null_results": [
    {
      "statement": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
      "evidence_line_ref": "L36"
    },
    {
      "statement": "ICI-only treatment had limited activity in low-immunogenic baseline settings.",
      "evidence_line_ref": "L37"
    },
    {
      "statement": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
      "evidence_line_ref": "L39"
    }
  ]
}